Introduction
Basic ®broblast growth factor (bFGF) is mitogenic for cells derived from neuroectoderm and mesoderm (Gospodarowicz, 1990) . Additionally, bFGF is a potent angiogenic factor in vivo (Folkman and Klagsbrun, 1987) . As a member of the FGF oncogene family which also includes aFGF, int-2, FGF-5, FGF-6, hst/K-FGF and KGF, bFGF has been suggested to play a crucial role in tumor progression. Strong evidence indicates that bFGF functions as an autocrine growth factor to stimulate cell growth and tumorigenesis of gliomas (Gross et al., 1990; Takahashi et al., 1990 Takahashi et al., , 1991 Takahashi et al., , 1992 Stefanik et al., 1991; Ueba et al., 1994) and hepatocellular carcinoma (Lobb et al., 1986; Klagsbrun et al., 1986; Shimoyama et al., 1991) . In human gliomas, the expression level of bFGF correlates with the degree of tumor malignancy (Takahashi et al., 1992) . Additionally, bFGF has been implicated in the progression of prostate cancer by potentiating metastatic growth (Gleave et al., 1992; Zuck et al., 1992; Nakamoto et al., 1992) . In addition to its role as a regulator of cell growth, bFGF appears to mediate resistance to radiation-induced apoptosis Fuks et al., 1994) .
Although there is signi®cant data indicating roles for bFGF in tumor growth and angiogenesis, less is known about the regulation of bFGF gene expression. The bFGF gene was cloned by Abraham et al. (1986) and its promoter was functionally characterized by Shibata et al. (1991) . Deletion analysis indicated two negative regulatory elements, one of which is in the upstream promoter region. It was reported that the bFGF promoter was induced by PMA and cAMP through cis regulatory elements (Stachowiak et al., 1994 ). An AP-1 element in the bFGF promoter has been shown to be functional in the transcriptional regulation of bFGF gene expression Erdos et al., 1995) . Moett et al. (1996) have identi®ed two regions in the promoter responsible for the regulation of bFGF gene activity by cell density. In some melanomas, bFGF is upregulated through the activation of the HoxB7 transcription factor (Care et al., 1996) . bFGF has been shown to upregulate the expression of bFGF mRNA (Weich et al., 1991) , indicating that bFGF can be autoregulated. While this manuscript was in preparation, it was shown that Egr-1 can activate transcription of the bFGF promoter (Biesiada et al., 1996) and is a likely function in mitogenic responses of astrocytes.
Egr-1 is a zinc ®nger transcriptional factor (see Gashler and Sukhatme, 1995) which was also identi®ed as NGFI-A (Milbrandt, 1987) , Zif268 (Lau and Nathans, 1987) , Cef5 (Simmons et al., 1989) , Krox24 (Lemaire et al., 1988) and Tis8 (Lim et al., 1987) . Similar to c-Fos, Egr-1 expression is rapidly induced by mitogens such as platelet-derived growth factor (PDGF), FGF and epidermal growth factor (EGF) in ®broblasts (Sukhatme et al., 1987; Lau and Nathans, 1987; Lemaire et al., 1988) , suggesting a possible role of Egr-1 in mediating bFGF autoregulation. In this study, we identi®ed two functional Egr-1 binding sites in the human bFGF promoter that function as positive regulatory elements. Our data indicate that the activation of Egr-1 binding in response to bFGF stimulation is responsible, at least in part, for the autoregulation of bFGF transcription. the bFGF gene. In order to address this question we utilized a plasmid with the bFGF promoter linked to the luciferase reporter gene (bFGF1.2Luc, containing bFGF sequences from 71000 to +160). The bFGF responsive human hepatocellular carcinoma cell line Hep3B (p53 7/7 ) was chosen for the transient transfection experiments. Following transfection with the bFGF1.2Luc reporter, cells were serum deprived and induced with human recombinant bFGF at a ®nal concentration of 40 ng/ml. There was no dierence in cell viability observed between the bFGF stimulated and nonstimulated controls. Luciferase assays indicated that bFGF signi®cantly activated the bFGF promoter-luciferase reporter (Figure 1 ). These results indicate that at least part of the mechanism for the upregulation of bFGF mRNA in response to bFGF stimulation is through a transcriptional response.
The bFGF promoter contains binding sites for Egr-1
In order to further explore the ability of bFGF to regulate the transcription of the gene encoding this growth factor, we analysed the bFGF promoter for binding sites for growth factor inducible transcription factors. Our computer search identi®ed two near perfect Egr-1 binding sites. Site C (GCGGGGGTG) is located in the promoter from 7165 to 7157 and site E (CGCCCCCGA) is located from 763 to 755 (Figure 2a) . Each sequence is a 8/9 match with the consensus site Egr-1 GCGGGGGCG (Gashler and Sukhatme, 1995) . Egr-1 is a growth factor and phorbol ester inducible transcription factor that is induced by new transcription and de novo synthesis (Maass et al., 1994; Gashler and Sukhatme, 1995) . In order to determine if Egr-1 bound to these sites, nuclear extracts from PMA-treated CEM cells were incubated with radiolabeled DNA probes from these two sites and were electrophoresed on nondenaturing gels. This electrophoretic mobility shift assay (EMSA) identi®ed a constitutive factor and an induced factor that bound to site E (see Figure 2b , lanes 1 ± 5). The induced factor was rapidly activated by PMA and binding remained elevated for over 4 h (Figure 2b and data not shown). Induction by PMA is a characteristic of Egr-1 (Gashler and Sukhatme, 1995) . Evidence that the inducible complex was in fact Egr-1 was addressed by two approaches. First, we showed that a consensus Egr-1 site competed for binding of the inducible complex but not the constitutive complex (Figure 2b , lanes 6 ± 9). Cold binding site probe from the bFGF promoter competed for both complexes (Figure 2b , lanes 10 ± 13), indicating that both complexes are speci®c. We utilized antibodies to Egr-1 and to Sp1, which often binds to a site overlapping Egr-1 sites, in an attempt to supershift the complexes seen in Figure  2b . Data shown in Figure 2c demonstrate that antibodies against Egr-1 supershifts the inducible complex and Sp1 antibodies supershift the constitutive complex (Figure 2c, lanes 3 and 4) . Additionally, our data indicate that both Sp1 and the inducible transcription factor Egr-1 bind to sites C and E with approximately equal anities (Figure 2d) . Recently, in agreement with our data, Biesiada et al. (1996) Figure 1 bFGF upregulates bFGF promoter. Hep3B cells were transfected with 3 mg of bFGF1.2Luc which links the bFGF promoter region (71000 to +160) to the luciferase reporter gene. Cells were stimulated with 40 ng/ml of human recombinant bFGF for 8 h following transfection. Whole cell lysate were made and luciferase activities were measured. The data is shown as mean+s.d.
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showed that Sp1 and Egr-1 bound to these identical sites.
Functional analysis of the bFGF promoter
In order to determine if the two Egr-1 binding sites confer transcriptional regulation in response to expression of Egr-1, we analysed several deletion constructs of the bFGF promoter (see Figure 3a) . Transfection of Hep3B cells with an expression vector for Egr-1 activated 2.0Luc and 1.2Luc approximately 8 ± 9 fold, but was more eective at activating 16/8Luc which has had a negative regulatory element deleted (see Figure 3b) . A further deletion to 7160 (22/2Luc) is signi®cantly impaired in its inducibility by Egr-1, likely due to the removal of Egr-1 site C. Construct 80/ 160Luc is weakened in its ability to respond to Egr-1, possibly due to the removal of two GC boxes of which one (CGCCCCCCG) is a possible Egr-1 binding site (789 to 780). Removal of site E signi®cantly blocked the response to Egr-1 (Figure 3b ). These data indicate that multiple regulatory elements in the bFGF 
Egr-1 bFGF stimulates synthesis of Egr-1 and induces Egr-1 binding to the bFGF promoter Although it was previously shown that bFGF leads to the synthesis of Egr-1 (Maass et al., 1994) , it was important for us to determine if a similar response would occur in Hep3B cells. Whole cell lysates of Hep3B cells stimulated with bFGF were immunoblotted with an antibody to Egr-1. Results shown in Figure 4a demonstrate that bFGF induces a signi®cant accumulation of Egr-1 protein in Hep3B cells. In order to determine if bFGF could induce Egr-1 binding to the bFGF promoter, we performed gel mobility shift experiments. Nuclear extracts from unstimulated Hep3B cells and from cells treated with bFGF for varying times were incubated with 32 P-labeled probe for Hep3B cells were incubated with 32 P-labeled probe E and were analysed on nondenaturing gel. Antibodies against Sp1 and Egr-1 were used (lanes 6 and 7) to detect Sp1 and Egr-1 bFGF autoregulation requires Egr-1 D Wang et al site E and were electrophoresed on nondenaturing gels. This experiment indicated that bFGF induced Egr-1 binding to the bFGF promoter but did not change the quantitative interaction of Sp1 with this site ( Figure   4b ). bFGF-induced Egr-1 protein can also bind to the C site (data not shown). This result leads to the obvious question of whether the transcriptional autoregulation function of bFGF is mediated by Egr-1. Egr-1 activates the bFGF promoter and is required for transcriptional regulation in response to bFGF stimulation
In order to determine if Egr-1 mediates the transcriptional response of the bFGF promoter to bFGF stimulation, we performed site directed mutagenesis on sites C and E (either individually or in tandem).
These constructs are shown in Figure 5a and the baseline level of expression of the dierent mutants is approximately the same in both Cos-7 cells and Hep3B cells (data not shown). In Cos-7 cells, both site C and E mutants led to signi®cantly reduced transactivation by Egr-1 in a transient transfection experiment. Mutation in both sites led to a further reduction in transcription directed by the bFGF promoter in response to expression of Egr-1 (Figure 5b ). Similar results were obtained using Hep3B as the recipient cells (data not shown). The fact that mutation of sites C and E did not fully block bFGF promoter activation in response to Egr-1 expression indicates the possibility that other Egr-1 sites exist in the bFGF promoter (+36 to +45 as implicated in Biesiada et al. (1996) and possibly 789 to 780). Deletion analysis of bFGF promoter by Biesiada et al. (1996) indicated that the Egr-1 binding site at 760 bp was unimportant for bFGF transactivation by Egr-1. Our data suggest that the two Egr-1 binding sites are both required for Egr-1 activation of bFGF promoter. Importantly, both mutants and the double mutant were impaired Figure 5c ). This latter result strongly indicates that Egr-1 directly interacts with the bFGF promoter and that this transcription factor is required for the ability of bFGF to stimulate the transcription of the bFGF promoter.
In order to further demonstrate that it is Egr-1 that is controlling the transcriptional response induced by bFGF, we utilized a dominant negative form of Egr-1. This construct contains the DNA-binding domain of Egr-1 fused to a transcriptional repression domain found in WT1 (Madden et al., 1991) . As shown in Figure 6a , co-transfection of the dominant negative construct with the bFGF-luciferase reporter blocked the transcriptional activation of this reporter in response to stimulation with bFGF. Importantly, the dominant negative was speci®c for blocking Egr-1 dependent transcription since the PMA-induced activation of an NF-kB dependent reporter was not blocked by this inhibitor (Figure 6b ). Further evidence for a role of Egr-1 in stimulating bFGF gene expression in response to bFGF stimulation is data indicating that an antisense construct to Egr-1 blocked the induced transcription of the bFGF promoter (Figure 7a ). The antisense Egr-1 was speci®c for blocking Egr-1 since it did not inhibit the PMA induced activation of the NFkB dependent reporter (Figure 7b ). The data are consistent with the recent report of Biesiada et al. (1996) in demonstrating the importance of Egr-1 in the regulation of bFGF gene expression. In addition, our data indicate that the activation of Egr-1 binding activity is responsible, at least in part, for the autoregulation of bFGF transcription.
Discussion
The human bFGF promoter does not contain TATA or CCAAT regulatory elements, but is known to contain an AP1 binding site and 5 GC boxes (see Shibata et al., 1991) . Our data and that of others indicate that some of these GC boxes are functionally important through interactions with the transcription factor Egr-1. Our work has focused on the role two of these elements, one centred at 7160 (GCGGGGGTC) and one centred at 760 (CGCCCCCGA), and how they contribute to bFGF autoregulation. We show that both of these sequences bind to Egr-1 and that both are required for full transcriptional response to transfected Egr-1 and to bFGF stimulation. Interestingly, Sp1 binds to a sequence that overlaps both of these Egr-1 sites. Overlapping Egr-1 and Sp1 binding sites have also been found in promoters of the Egr-1 (Cao et al., 1993) , the tumor necrosis factor a (Kramer et al., 1994) , the human IL-2 (Skerka et al., 1995) , the human platelet-derived growth factors (PDGF) Achain (Khachigian et al., 1995) , PDGF-B (Khachigian et al., 1996) , the human NF-KB1 (Cogswell et al., 1997) , the human tissue factor (Cui et al., 1996) , the mouse adenosine deaminase (Ackermann et al., 1991) , the mouse thrombospondin 1 (Shingu and Bornstein, 1994) and the rat phenylethanolamine N-methyltransferase genes (Ebert and Wong, 1995) . It appears that binding of Sp1 and Egr-1 are mutually exclusive. Studies of PDGF-A and PDGF-B genes (Khachigian et al., 1994 (Khachigian et al., , 1995 suggest that Sp1 mediates basal expression of the genes and PMA induced Egr-1 displaces Sp1 from the G+C rich element and stimulates gene expression. Our binding and cotransfection data (not shown) indicate that Sp1 and Egr-1 do not interact with each other and they do not synergize in the regulation of human bFGF promoter, suggesting that a similar model can be applied in our studies. Accordingly, the exchange of Sp1 and Egr-1 at overlapping elements may be an important common event in the control of inducible gene expression. Additionally, the bFGF promoter contains a functional AP-1 site. Very similar to Egr-1, c-jun and c-fos expression are rapidly activated by bFGF (Hall et al., 1991; Ito et al., 1990; Lampugnani et al., 1990; Thomson et al., 1990) . It is therefore possible that AP-1 also controls the response to bFGF. The AP-1 site is located at 7230 bp. Our transient transfection data (not shown) indicate that AP-1 and Egr-1 do not synergize in the bFGF promoter. The fact that a dominant negative form of Egr-1 blocks the response of the bFGF promoter to bFGF stimulation indicates that Egr-1 is required for the bFGF induced transcription of the bFGF promoter. AP-1 is therefore less important in the control of the response to bFGF.
Egr-1 is a zinc ®nger protein that binds with the high anity to the sequence GCGGGGGCG (Gashler and Sukhatme, 1995) . The primary level of control of activation of Egr-1 is thought to be through its induced transcription and subsequent translation. Thus, Egr-1 is an immediate early protein in response to a variety of extracellular stimuli such as growth factors. Others have shown (Maass et al., 1994) and we have con®rmed that bFGF induces the synthesis of Egr-1 protein, presumably through the activation of transcription. Additionally, we show that bFGF enhances the binding of Egr-1 to the Egr-1 binding sites in the bFGF promoter. Stimulation of the bFGFR is known to activate MAP kinases (Thomas et al., 1992; Wood et al., 1992) and MAP kinase homologs JNK and p38 (Kyriakis et al., 1994) . For example, bFGF can induce CREB phosphorylation by activating p38 kinase (Tan et al., 1996) . bFGF autoregulation may be involved in multiple signal pathways initiated at the bFGF receptor. The Egr-1 promoter is known to contain multiple serum response elements (SREs) which are activated by MAP kinase controlled signal transduction pathways (Tsai-Morris et al., 1988) . It has been shown that the DNA binding activity of Egr-1 can be enhanced by phosphorylation (Huang and Adamson, 1994) . Thus, it is possible that bFGF regulates Egr-1 activity both by inducing transcription of the gene encoding this transcription factor and by activation of a signal transduction pathway leading to its phosphorylation. Additionally, mitogenic signals have been shown to enhance the translation of Egr-1 (Maass et al., 1994) ; thus other levels of control may be operative in the activation of Egr-1.
bFGF is a potent mitogen for a number of cell types and bFGF expression levels correlate with degree of malignancy and vascularity of human gliomas (Takahashi et al., 1992) . Consistent with our results, Egr-1 is strongly activated by several glial mitogens (Arenander et al., 1989) and bFGF overexpression in the glioblastoma cell line U87MG correlates with high levels of Egr-1 protein (data not shown). Recently, it was shown that a neutralizing antibody to bFGF bFGF autoregulation requires Egr-1 D Wang et al blocked the in vivo tumor growth and angiogenesis of U87MG (Stan et al., 1995) , indicating a function for secreted bFGF and suggesting that bFGF may play a critical role in the growth of these cells. Consistent with this observation are the results of Murphy et al. (1992) who showed that antisense to bFGF blocked anchorage-independent growth of the U87MG cell line. Our data presented here indicate that a critical downstream eector of bFGF function is the Egr-1 transcription factor. Activation of Egr-1 is suggested to be involved in the regulation of the G 0 /G 1 transition in mammalian cells (Lemaire et al., 1990) . Besides bFGF, Egr-1 also targets many other growth factors and growth factor receptors such as PDGF-A, B (Khachigian et al., 1995 (Khachigian et al., , 1996 , tissue factor (Cui et al., 1996) and possibly epidermal growth factor receptor, suggesting that activation of Egr-1 may play a common role in the formation of a positive feedback autocrine loop, which is often involved in the mitogenic pathways and transformation. Indeed, overexpression of Egr-1 has been found in many transformed cells, such as v-sis transformed cells (Grover-Bardwick et al., 1994) and G a13 transformed NIH3T3 cells (Vara Prasad et al., 1994) . Our data support the role of Egr-1 in cell transformation. Most importantly, our data suggest that Egr-1 may play a critical role in the tumorigenic properties of glioblastomas and potentially other types of tumors.
Materials and methods

Cell structure
Hep3B cells were grown in Dulbecco's Modi®ed Eagles Media. Cos-7 cells were grown in Iscove's Modi®ed Eagles Media. CEM cells were grown in RPMI1640. All media were supplemented with 10% FBS, penicillin and streptomycin.
Preparation of nuclear extracts and electrophoretic mobility shift assay Nuclear and cytoplasmic extracts from CEM and Hep3B cells were prepared as previously described (Beg et al., 1993) . EMSA were performed as described in Skerka et al. (1995) . Probe C was created by annealing the two oligonucleotides 5'-TCGAGGTTGGGCGGGGGTGAC-TTTTGGGGGATAAGGGGCGGTGG-3' and 5'-TCGA-CCACCGCCCCTTATCCCCCAAAAGTCACCCCCGCC-CAACC-3'. Probe E was created by annealing the two oligonucleotides 5'-TCGACGCCTCTCCCCCGCCCCC-GACTGAG-3' and 5'-TCGACTCAGTCGGGGGCG-GGGGAGAGGCG-3' (binding site for Egr-1 is in boldface type). The Egr-1 consensus site which was made by annealing two oligonucleotides 5'-TCGACTC-CGCCCCCGCTGCG-3' and 5'-TCGACGCAGCGGG-GGCGGGAG-3' was provided by Patty Cogswell.
Plasmid constructs
2.0Luc, 22/2Luc, and 16/8Luc were generous gifts of Dr Robert Z Florkiewicz. CMV-Egr-1 and CMV-Wt1/Egr-1 were kindly provided by Dr Vikas P Sukhatme. 1.2Luc, 500/160Luc, 80/160Luc and 50/160Luc were created by cloning the dierent PCR products into pGL2 Basic (promega) XhoI and HindIII sites. The PCR reactions were performed using 5'-AAGCTCGAGCAAATCTC-CTGCCTCCCCAC-3' (1.2Luc) or 5'-CCCCTCGAGCT-CCCCTTCTCTGGCCTCT-3' (500/160Luc) or 5'-GCCCT-CGAGCTCTCCCCCGCCCCCGACTGA-3' (80/160Luc) or 5'-GCCCTCGAGCCCGCCGGACTGATGTCG-3' (50/ 160Luc) and 5'-AACAAGCTTCACCGTCCGCTAATCT-GGCA-3' as primers, using 2.0Luc as template. 500/ 160Luc was subjected to site-directed mutagenesis using two-staged PCR (Cogswell et al., 1997) . The templates for the ®rst round were 500/160Luc for 7160 m and 760 m and 7160 m for double mutant. The primers used were (1) 5'-CCCCTCGAGCTCCCCTTCTCTGGCCTCT-3' (2) 5'-AACAAGCTTCACCGTCCGCTAATCTGGCA-3' (3) 5'-GGCCTCAGTCGGTTAAGGGGGGAGAGGCGAGGG-3' (4) 5'-TCGCCTCTCCCCCTTAACCGACTGAGGCC-GGGC-3' (5) 5'-GCGGGGGTGGGGTTAAGGTGACT-TTTGGGGGA-3' (6) 5'-CCCAAAAGTCACCTTAACC-CAACCC (boldface type indicates the mutated nucleotides). The products of second round PCR were cloned into the XhoI and HindIII sites of pGL2 basic.
Transient transfection and luciferase assay
Hep3B cells and Cos-7 cells were transfected using lipofectAMIN(Gibco BRL). Cells were seeded 24 h prior to transfection at 8610 5 cells/100 mm plate for Hep3B cells and 4610 5 cells/100 mm plate for Cos-7 cells. A total of 3 ± 4 mg of DNA (2 ± 3 mg of reporter and 1 mg of expression vector) and 18 ml of lipofectAMIN were incubated with 600 ml OPTI-MEM (Gibco BRL) at room temperature for 30 min before adding to the cells with 4.5 ml OPTI-MEM. Salmon sperm DNA was used to normalize the amount of DNA for each sample. The mixtures were left on the cells at 378C for 6 h then washed with PBS and replaced with complete media. 36 to 48 h after transfection, cells were harvested and assayed for luciferase activities. For bFGF induction, cells were serum deprived for 12 h after 1 day in complete media and induced with recombinant human bFGF (R&D systems) at 40 ng/ml for 8 h. For PMA induction, transfected cells were induced with 50 ng/ml PMA (Sigma) for 12 h before harvest. Whole cell lysates were made by freeze/thaw three times in 0.25 M Tris.HCl (pH 7.6). Luciferase assays were performed by methods described elsewhere (Cogswell et al., 1997) .
Western blot assay
A total of 50 mg of whole cell lysate was electrophoresed on an 8% polyacrylamide gel. Proteins were transferred to nitrocellulose and blots were blocked with 5% dry milk, then probed with Egr-1 antibody (1 : 1500, Santa Cruz). After the blots were incubated with secondary antibody (which was conjugated with horseradish peroxidase), ECL reagents (Amersham) were used to detect the Egr-1 protein.
